Advertisement

Journal of Neuro-Oncology

, Volume 124, Issue 3, pp 485–491 | Cite as

Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery in patients with 1–3 newly diagnosed brain metastases

  • Manmeet S. Ahluwalia
  • Samuel T. Chao
  • Michael W. Parsons
  • John H. Suh
  • Ding Wang
  • Tom Mikkelsen
  • Cathy J. Brewer
  • Kathy N. Smolenski
  • Cathy Schilero
  • Matthew Rump
  • Paul Elson
  • Lilyana Angelov
  • Gene H. Barnett
  • Michael A. Vogelbaum
  • Robert J. Weil
  • David M. PeereboomEmail author
Clinical Study

Abstract

Patients with 1–3 brain metastases (BM) often receive sterotactic radiosurgery (SRS) without whole brain radiotherapy (WBRT). SRS without WBRT carries a high rate of relapse in the central nervous system (CNS). This trial used sunitinib as an alternative to WBRT for post-SRS adjuvant therapy. Eligible patients with 1–3 newly diagnosed BM, RTOG RPA class 1–2, received sunitinib after SRS. Patients with controlled systemic disease were allowed to continue chemotherapy for their primary disease according to a list of published regimens (therapy + sunitinib) included in the protocol. Patients received sunitinib 37.5 or 50 mg/days 1–28 every 42 days until CNS progression. Neuropsychological testing and MRIs were obtained every two cycles. The primary endpoint was the rate of CNS progression at 6 months (PFS6) after SRS. Fourteen patients with a median age of 59 years were enrolled. Primary cancers included lung 43 %, breast 21 %, melanoma 14 %. Toxicity included grade 3 or higher fatigue in five patients and neutropenia in two patients. The CNS PFS6 and PFS12 were 43 ± 14 and 34 ± 14 %, respectively. Of the ten patients who completed >1 neurocognitive assessment, none showed cognitive decline. Sunitinib after SRS for 1–3 BM was well tolerated with a PFS6 of 43 %. The prevention of progressive brain metastasis after SRS requires the incorporation of chemotherapy regimens to control the patient’s primary disease. Future trials should continue to explore the paradigm of secondary chemoprevention of BM after definitive local therapy.

Keywords

Sunitinib Stereotactic radiosurgery Brain metastases Secondary prevention Neuropsychological testing Phase 2 

Notes

Funding

Pfizer Pharmaceuticals

Compliance with ethical standards

Conflict of interest

DMP, research funding Pfizer Pharmaceuticals

Supplementary material

11060_2015_1862_MOESM1_ESM.docx (27 kb)
Supplementary material 1 (DOCX 27 kb)
11060_2015_1862_MOESM2_ESM.xlsx (1.7 mb)
Supplementary material 2 (XLSX 1693 kb)

References

  1. 1.
    Kaal EC, Niel CG, Vecht CJ (2005) Therapeutic management of brain metastasis. Lancet Neurol 4:289–298CrossRefPubMedGoogle Scholar
  2. 2.
    Delattre JY, Krol G, Thaler HT, Posner JB (1988) Distribution of brain metastases. Arch Neurol 45:741–744CrossRefPubMedGoogle Scholar
  3. 3.
    Sundstrom JT, Minn H, Lertola KK, Nordman E (1998) Prognosis of patients treated for intracranial metastases with whole-brain irradiation. Ann Med 30:296–299CrossRefPubMedGoogle Scholar
  4. 4.
    Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745–751CrossRefPubMedGoogle Scholar
  5. 5.
    Borgelt B, Gelber R, Kramer S, Brady LW, Chang CH, Davis LW, Perez CA, Hendrickson FR (1980) The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 6:1–9CrossRefPubMedGoogle Scholar
  6. 6.
    Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494–500CrossRefPubMedGoogle Scholar
  7. 7.
    Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran WJ Jr (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363:1665–1672CrossRefPubMedGoogle Scholar
  8. 8.
    Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, Markesbery WR, Foon KA, Young B (1998) Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280:1485–1489CrossRefPubMedGoogle Scholar
  9. 9.
    Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura H, Kunieda E, Inomata T, Hayakawa K, Katoh N, Kobashi G (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295:2483–2491CrossRefPubMedGoogle Scholar
  10. 10.
    Aoyama H, Tago M, Shirato H, for the Japanese Radiation Oncology Study Group 99–1 (JROSG 99–1) Investigators (2015) Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: secondary analysis of the JROSG 99-1 randomized clinical trial. JAMA Oncol 1:E1–E8CrossRefGoogle Scholar
  11. 11.
    O’Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597–3605CrossRefPubMedGoogle Scholar
  12. 12.
    Kim LS, Huang S, Lu W, Lev DC, Price JE (2004) Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin Exp Metastasis 21:107–118CrossRefPubMedGoogle Scholar
  13. 13.
    Roodink I, van der Laak J, Kusters B, Wesseling P, Verrijp K, de Waal R, Leenders W (2006) Development of the tumor vascular bed in response to hypoxia-induced VEGF-A differs from that in tumors with constitutive VEGF-A expression. Int J Cancer 119:2054–2062CrossRefPubMedGoogle Scholar
  14. 14.
    Benedict R, Schretlen D, Groninger L, Brandt J (1998) Hopkins Verbal Learning Test: Revised—Normative data and analysis of inter-form and test-retest reliablity. Clin Neuropsychol 12:43–55CrossRefGoogle Scholar
  15. 15.
    Benton A, Hamsher K, Sivan A (1983) Multilingual Aphasia examination. AJA Associates, Iowa CityGoogle Scholar
  16. 16.
    Lezak MD (2004) Neuropsychological assessment, 4th edn. Oxford University Press, OxfordGoogle Scholar
  17. 17.
    Jacobson NS, Truax P (1991) Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 59:12–19CrossRefPubMedGoogle Scholar
  18. 18.
    Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, Kunkler I, Caudrelier JM, Eisenberg PD, Meerwaldt J, Siemers R, Carrie C, Gaspar LE, Curran W, Phan SC, Miller RA, Renschler MF (2004) Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 22:157–165CrossRefPubMedGoogle Scholar
  19. 19.
    Frytak S, Shaw JN, O’Neill BP, Lee RE, Eagan RT, Shaw EG, Richardson RL, Coles DT, Jett JR (1989) Leukoencephalopathy in small cell lung cancer patients receiving prophylactic cranial irradiation. Am J Clin Oncol 12:27–33CrossRefPubMedGoogle Scholar
  20. 20.
    Sperduto PW, Wang M, Robins HI, Schell MC, Werner-Wasik M, Komaki R, Souhami L, Buyyounouski MK, Khuntia D, Demas W, Shah SA, Nedzi LA, Perry G, Suh JH, Mehta MP (2013) A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys 85:1312–1318CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Massard C, Zonierek J, Gross-Goupil M, Fizazi K, Szczylik C, Escudier B (2010) Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol 21:1027–1031CrossRefPubMedGoogle Scholar
  22. 22.
    Verma J, Jonasch E, Allen P, Tannir N, Mahajan A (2011) Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. Cancer 117:4958–4965CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Manmeet S. Ahluwalia
    • 1
    • 2
    • 6
  • Samuel T. Chao
    • 1
    • 2
    • 6
  • Michael W. Parsons
    • 1
    • 4
  • John H. Suh
    • 1
    • 2
    • 6
  • Ding Wang
    • 3
  • Tom Mikkelsen
    • 3
  • Cathy J. Brewer
    • 1
    • 2
    • 6
  • Kathy N. Smolenski
    • 1
    • 2
    • 6
  • Cathy Schilero
    • 1
    • 2
    • 6
  • Matthew Rump
    • 2
    • 4
  • Paul Elson
    • 2
    • 4
  • Lilyana Angelov
    • 1
    • 6
  • Gene H. Barnett
    • 1
    • 6
  • Michael A. Vogelbaum
    • 1
    • 6
  • Robert J. Weil
    • 5
  • David M. Peereboom
    • 1
    • 2
    • 6
    Email author
  1. 1.Neurological InstituteCleveland ClinicClevelandUSA
  2. 2.Taussig Cancer InstituteCleveland ClinicClevelandUSA
  3. 3.Henry Ford HospitalDetroitUSA
  4. 4.Quantitative Health Sciences, Lerner Research InstituteCleveland ClinicClevelandUSA
  5. 5.Geisinger Medical CenterDanvilleUSA
  6. 6.Cleveland Clinic Lerner College of Medicine, The Rose Ella Burkhardt Brain Tumor & Neuro-Oncology Center, Solid Tumor OncologyCleveland ClinicClevelandUSA

Personalised recommendations